Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Cellular Oncology (Dordrecht, Netherlands)|February 26, 2025
Thymidine kinase 1 indicates resistance to immune checkpoint plus tyrosine kinase inhibition in renal cell carcinomaJiajun Wang, Xianglai Xu, Ying Wang, et al.
European Journal of Pharmacology|September 5, 2025
KPNA2 Expression as a Biomarker for Immunosuppressive Microenvironment Predicting Response to TKI and Immunotherapy in Metastatic Renal Cell CarcinomaXianglai Xu, Xin Xie, Jiajun Wang, et al.
Evolutionary Bioinformatics Online|November 4, 2021
Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by BioinformaticsXianglai Xu, Yelin Wang, Sihong Zhang, et al.
Neoplasia (New York, N.Y.)|July 30, 2023
Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patientsXianglai Xu, Ying Wang, Xinyu Hu, et al.
Immunogenetics|December 14, 2022
Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expressionXianglai Xu, Ying Wang, Zhaoyi Chen, et al.
European Journal of Pharmacology|April 5, 2026
Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinomaLingzhi Du, Jiahao Wang, Ying Wang, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 2, 2024
PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitorsXianglai Xu, Jiahao Wang, Ying Wang, et al.
BMC Urology|January 3, 2024
RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Cancer Medicine|April 9, 2023
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinomaXianglai Xu, Sihong Zhang, Ying Wang, et al.
Scandinavian Journal of Immunology|June 9, 2023
The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibitionJiajun Wang, Sihong Zhang, Ying Wang, et al.
Pageof 4